Type 1 & Type 2 Diabetes • ICD-10-CM R73.02
Glucose intolerance
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM R73.02 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Glucose intolerance Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Glucose intolerance (R73.02; Type 1 & Type 2 Diabetes) utilize urine microalbumin-to-creatinine ratios [Glucose intolerance R73.02] and objective Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02] targets (4.8% – 5.6% (< 6.5% clinical target) (R73.02)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code R73.02 categorizes Glucose intolerance under Type 1 & Type 2 Diabetes.
- 3 Typical cash cost range: Workup highlights for Glucose intolerance (R73.02): urine microalbumin-to-creatinine ratios [Glucose intolerance R73.02].
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Glucose intolerance (R73.02): Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02] & Fasting Plasma Glucose [Glucose intolerance R73.02] (75 – 95 mg/dL (R73.02)).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Glucose intolerance
What Is Glucose intolerance?
Physicians managing Glucose intolerance (R73.02; Type 1 & Type 2 Diabetes) utilize urine microalbumin-to-creatinine ratios [Glucose intolerance R73.02] and objective Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02] targets (4.8% – 5.6% (< 6.5% clinical target) (R73.02)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Glucose intolerance (R73.02, Diabetes & Glucose) reflects progressive pancreatic beta-cell in Glucose intolerance (R73.02: exhaustion). longitudinal control is benchmarked via Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02].
Common Symptoms & Clinical Signs
- • Presentation of Glucose intolerance (R73.02): blurred vision fluctuations in Glucose intolerance (R73.02: or slower healing)
- • Secondary Glucose intolerance clinical sign: elevated fasting blood in Glucose intolerance (R73.02: glucose or post-meal)
- • Symptom flares in Glucose intolerance correlating with Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (R73.02)
- • Functional diabetes & glucose impact requiring urine microalbumin-to-creatinine ratios [Glucose intolerance R73.02] evaluation (R73.02)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Glucose intolerance Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R73.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Glucose intolerance R73.02] | 4.8% – 5.6% (< 6.5% clinical target) (R73.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Glucose intolerance R73.02] | 75 – 95 mg/dL (R73.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Glucose intolerance R73.02] | 3.0 – 7.0 uIU/mL (R73.02) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Glucose intolerance
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Glucose and Sodium Chloride (Dextrose Anhydrous and Sodium Chloride) Glucose and Sodium Chloride • RxCUI RXN-B03389799 | Osmotic Laxative | 87% | $3.2000 | $ 238.90 /mo |
| Dapagliflozin and Saxagliptin Dapagliflozin and Saxagliptin Generic • RxCUI RXN-72205438-2440 | Sodium-Glucose Cotransporter 2 Inhibitor | 75% | $11.4327 | $ 185.00 /mo |
| Empagliflozin, Metformin Hydrochloride Synjardy XR, Synjardy • RxCUI 1862685 | Sodium-Glucose Cotransporter 2 Inhibitor | 82% | $11.2090 | $ 185.00 /mo |
| Jardiance (Empagliflozin) Jardiance • RxCUI 1545658 | Sodium-Glucose Cotransporter 2 Inhibitor | 80% | $1.8400 | $ 140.98 /mo |
| Mounjaro (Tirzepatide) Mounjaro • RxCUI 2601767 | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist | 92% | $523.0483 | $ 640.00 /mo |
| Farxiga (Dapagliflozin) Farxiga • RxCUI 1488574-B705184614 | Sodium-Glucose Cotransporter 2 Inhibitor | 92% | $12.0765 | $ 7.07 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glucose intolerance)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Glucose levels predict hospitalization for congestive heart failure in patients: What a 25,620-Participant Study Found Fasting plasma glucose is an independent predictor of hospitalization for CHF in high-risk subjects. Circulation • 2007-03-20 • Randomized Controlled Trial | N = 25,620 | 96/100 | PMID 17339550 ↗ |
| Check Your Medicine Cabinet: Hospital Glucose Meter Correction: Nova Biomedical Updates Use Instructions for StatStri Indexed from FDA MedWatch Safety Alerts (2026-10-30) by DotMD's 2-hour clinical surveillance pipeline. FDA MedWatch Safety Alerts • 2026-10-30 • FDA Safety Alert | Multi-cohort | 95/100 | PMID FDA_MEDWATCH-1688403489 ↗ |
| Can This Approach Help? Inside the Latest Research on Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Indexed from New England Journal of Medicine (2026-10-14) by DotMD's 2-hour clinical surveillance pipeline. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 95/100 | PMID NEJM-1332772225 ↗ |
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Glucose intolerance Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Glucose intolerance community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Glucose intolerance.